Coeptis Therapeutics

INNOVATIVE CELL
therapy
platforms
in oncology

Coeptis Therapeutics is a biopharmaceutical
company developing innovative cell therapy
platforms for patients with cancer.

About Coeptis

OUR Mission:
TO IMPROVE outcomes for patients with cancer

Our Science

Involves innovative cell therapy platforms

About Us

Coeptis Therapeutics is a biopharmaceutical company developing innovative cell therapy platforms for patients with cancer

Investors & Media

For more information regarding Press Releases, stock information

Our Science

Cancer Cell

LEARN MORE

IMMUNOTHERAPY CHALLENGES

Various immunotherapies for CD38+ tumors are designed to find and kill cells that express the CD38 antigen; therefore, CD38+ NK cells are likely to become collateral damage and with their eradication, the overall anti-tumor response is suboptimal.

THE GOAL

To protect CD38+ Natural Killer (NK) cells so that functional disease-targeting NK cells will not be eradicated, enabling their co-existence with CD38 targeting therapies, and thus allowing tumor killing and immune surveillance.

A NOVEL COMBINATORIAL APPROACH

Modified NK cells that are co-administered with select monoclonal antibodies and/or other CD38 targeting immunotherapies are in pre-clinical development to enhance and maximize tumor kill via combinatorial approaches otherwise not possible.

Our Science

IMMUNOTHERAPY CHALLENGES

Various immunotherapies for CD38+ tumors are designed to find and kill cells that express the CD38 antigen; therefore, CD38+ NK cells are likely to become collateral damage and with their eradication, the overall anti-tumor response is suboptimal.

THE GOAL

To protect CD38+ Natural Killer (NK) cells so that functional disease-targeting NK cells will not be eradicated, enabling their co-existence with CD38 targeting therapies, and thus allowing tumor killing and immune surveillance.

A NOVEL COMBINATORIAL APPROACH

Modified NK cells that are co-administered with select monoclonal antibodies and/or other CD38 targeting immunotherapies are in pre-clinical development to enhance and maximize tumor kill via combinatorial approaches otherwise not possible.

Cancer Cell

LEARN MORE

For Investors

Coeptis Therapeutics, Inc. conducts its commercial operations primarily through its wholly-owned subsidiary Coeptis Pharmaceuticals, Inc.

LEARN MORE

Coeptis Team

Leadership Team

Scientific
Advisory Board

Board of Directors

In the News

To get the latest News articles and Press Releases, click on the learn more link below

LEARN MORE

Contact Us